TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05909670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Advice and Support Text and Telephone (FASTT) program
Description: The Family Advice Support Text and Telephone (FASTT) service is a telehealth model that provides on-demand, evidence-based advice and support to reduce child behavior problems, address concerns about child development, and help manage stress for caregivers of children with DD. By using text and telephone, which are widely available without disparities in access by race, ethnicity, or socioeconomic status, FASTT overcomes barriers associated with videoconferencing which requires dependable Internet and familiarity with technology use. FASTT allows support to be delivered at times and locations that are convenient for the caregiver.
Study: NCT05522582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate tablets
Description: Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
Study: NCT05707442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent Implantation
Description: Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide-based medical therapy
Description: The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
Study: NCT05385367

Intervention type: OTHER
Group type: OTHER
Intervention: Regional anesthetic
Description: Patient having just the nerve block for surgery

Intervention type: OTHER
Group type: OTHER
Intervention: General anesthetic
Description: Patient having just general anesthetic ie. 'go completely under' for surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Combined general anesthetic and regional anesthetic
Description: Patient having a combination of a nerve block and general anesthetic for surgery
Study: NCT05601219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADA-011
Description: ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADA-011
Description: ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADA-011
Description: ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD(L)-1 inhibitor
Description: PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
Study: NCT06056895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo CT/MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuparstobart
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verzistobart
Description: Given IV
Study: NCT05259072

Intervention type: DIAGNOSTIC_TEST
Intervention: 99m-technetium pyrophosphate scintigraphy
Description: Imaging test
Study: NCT05557799

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
Study: NCT05023772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Laser Ablation
Description: MR Guided laser ablation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Precise delivery of radiation to spinal tumor

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI guided laser ablation
Description: Surgery will take place in intraoperative suite to include operating room and MRI scanner
Study: NCT06519071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan Intake
Description: Each hourly meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 Resting Energy Expenditure and adequate protein (at 1.5 g.kg.d), to maintain a metabolic steady state. The liquid shake contains protein-free powder orange-flavored drink crystals, corn oil, and water.
Study: NCT04729387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
Study: NCT04656691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bamlanivimab
Description: Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
Study: NCT04943185

Intervention type: DEVICE
Group type: OTHER
Intervention: XEN gel microstent implantation
Description: Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention

Intervention type: DEVICE
Group type: OTHER
Intervention: XEN gel microstent implantation
Description: Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention
Study: NCT04889456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implementation standardised laparoscopic right hemicolectomy with proctoring
Description: Implementation standardised laparoscopic right hemicolectomy with proctoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implementation standardised laparoscopic right hemicolectomy without proctoring
Description: Implementation standardised laparoscopic right hemicolectomy without proctoring
Study: NCT05071456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collects of skin's hydration
Description: Collects of skin's hydration will be made by using patch using electrochemistry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collects of skin's hydration
Description: Collects of skin's hydration will be made by using patch using electrochemistry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collects of skin's hydration
Description: Collects of skin's hydration will be made by using patch using electrochemistry.
Study: NCT04104945

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-intensified chemoradiotherapy
Description: Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
Study: NCT06221930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attexis
Description: Participants will receive access to the digital health intervention attexis in addition to TAU.
Study: NCT06446622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
Study: NCT05084235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matches the active drug in appearance, odor and labelling
Study: NCT04767581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KHK7791
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT05600387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: subjects in Empagliflozin group take 10mg Empagliflozin per day
Study: NCT05704023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder to exercise
Description: Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
Study: NCT05633459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of QRL-201
Description: Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple ascending doses of Placebo
Description: Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRL-201
Description: QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
Study: NCT05612061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indigenous Recovery Planning
Description: The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future.
Study: NCT05675722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biologic vaginal-construct implantation
Description: biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
Study: NCT06495060

Intervention type: OTHER
Intervention: No intervention (Only observation)
Description: No intervention

Intervention type: OTHER
Intervention: No intervention (Only observation)
Description: No intervention
Study: NCT06112262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Comparison between heparin and hirudin
Study: NCT06012825

Intervention type: BEHAVIORAL
Intervention: Physical Activity
Description: The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min).

Intervention type: BEHAVIORAL
Intervention: Physical Activity
Description: The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min).
Study: NCT06311721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 234
Description: Intravenous administration
Study: NCT04733833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 + Standard of care
Description: Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
Study: NCT06198868

Intervention type: PROCEDURE
Intervention: Operable
Description: Enrolled patients capable of surgical treatment
Study: NCT05776199

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sonoelastography, tensiomyography and mechanosensitivity
Description: To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sonoelastography, tensiomyography and mechanosensitivity
Description: To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
Study: NCT05545215

Intervention type: DEVICE
Intervention: Dexyane Med
Description: Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
Study: NCT05156853

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Insect menus
Description: The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant menus
Description: The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
Study: NCT05937204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Teaching
Description: A nursing teaching scheme refers to a systematic and structured plan developed by nurses to provide teaching and instruction to patients. The components of a nursing teaching scheme typically include assessing learning needs, setting learning objectives, developing teaching materials, delivering information using various teaching methods, demonstrating skills, providing written instructions, assessing learning outcomes, and conducting follow-up
Study: NCT04733833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT04936386

Intervention type: BEHAVIORAL
Intervention: Survey
Description: The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
Study: NCT06510881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinoplasty with or without cleft alveolus repair
Description: * Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinoplasty with or without cleft alveolus repair
Description: * Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years .
Study: NCT05619705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy for Two-Health Coaching (H42)
Description: The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintain Healthy in Pregnancy and Postpartum(mHIPP)
Description: A brief video on maternal warning signs that is available in English or Spanish.
Study: NCT06311721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (US)
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (EU)
Description: Intravenous administration
Study: NCT06065995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StoMakker
Description: A mobile application that offers age dependent information, a peer support platform and a game
Study: NCT05139316

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: DTX401
Description: nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Description: Participants who receive DTX401 solution will receive oral corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Description: Participants who receive DTX401 solution will receive oral corticosteroids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral corticosteroids
Description: Participants who receive DTX401 solution will receive oral corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for oral corticosteroids
Description: Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for oral corticosteroids
Description: Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
Study: NCT05325151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive GCPP intervention videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Receive genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04752774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Powder and solvent for solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Powder and solvent for solution for injection
Study: NCT06503848

Intervention type: DRUG
Intervention: Sumatriptan
Description: Register the response to treatment and headache characteristics.
Study: NCT05549232

Intervention type: DEVICE
Intervention: Hypoxic Red Blood Cells
Description: Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced

Intervention type: DEVICE
Intervention: Hypoxic Red Blood Cells
Description: Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced